Focus on niche markets, efficiency turn Biogen around

12/6/2012 | Forbes

George Scangos has turned around Biogen Idec by getting out of highly competitive markets, such as oncology, and focusing on areas where Big Pharma sometimes fears to tread, such as neuroscience and hemophilia. Sales chief Tony Kingsley's strategy of focusing on top-selling drug Avonex instead of the troubled multiple sclerosis drug Tysabri kept revenue flowing and allowed the company to develop BG-12, an MS drug in pill form instead of an injection. Now Scangos is cutting the bureaucracy usually inherent in drug development to refill the company's pipeline.

View Full Article in:

Forbes

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC